The expression profile for the tumour suppressor gene PTEN and associated polymorphic markers

British Journal of Cancer

Volumn 82, Issue 10, 2000, Pages 1671-1676

  Hamilton, J A ^a   Stewart, L M D ^a   Ajayi, L ^b   Gray, I C ^a,c   Gray, N E ^a,d   Roberts, K G ^a   Watson, G J ^a   Kaisary, A V ^b   Snary, D ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Microsatellite markers; Polymorphisms; Prostate; PTEN; Transcription

Indexed keywords

MESSENGER RNA; MICROSATELLITE DNA;

ADVANCED CANCER; ARTICLE; CHROMOSOME 10Q; GENE AMPLIFICATION; GENE CONSTRUCT; GENE EXPRESSION; GENE LIBRARY; GENE LOCATION; GENE MAPPING; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; HAPLOTYPE; HETEROZYGOSITY LOSS; HUMAN; INTRON; MOLECULAR CLONING; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; POLYADENYLATION; PRIORITY JOURNAL; PROSTATE CANCER; PSEUDOGENE; START CODON; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE; YEAST ARTIFICIAL CHROMOSOME;

ALTERNATIVE SPLICING; BLOTTING, NORTHERN; CHROMOSOME MAPPING; CHROMOSOMES, ARTIFICIAL, YEAST; CHROMOSOMES, BACTERIAL; CHROMOSOMES, HUMAN, PAIR 10; GENES, TUMOR SUPPRESSOR; GENETIC MARKERS; HUMANS; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS; PHOSPHORIC MONOESTER HYDROLASES; POLYMORPHISM, GENETIC; PTEN PHOSPHOHYDROLASE; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 0034014706     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Aveyard JS, Skilleter A, Habuchi T and Knowles MA (1998) Somatic mutation of PTEN in bladder cancer. Br J Cancer 80: 904-908
2. Bose S, Wang SI, Terry MB, Hibshoosh H and Parsons R (1998) Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas. Oncogene 17: 123-127
3. Brownstein MJ, Carpten JD and Smith JR (1996) Modulation of non-templated nucleotide addition by Taq DNA polymerase: primer modifications that facilitate genotyping. Biotechniques 20: 1004-1010
4. Cairns P, Evron E, Okami K, Halachmi N, Esteller M, Herman JG, Bose S, Wang SI, Parsons R and Sidransky D (1998) Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene 16: 3215-3218
5. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, Isaacs WB, Bova GS and Sidransky D (1997) Frequent inactivation of PTEN/MMAC1 in primary prostate-cancer. Cancer Res 57: 4997-5000
6. Cheney IW, Johnson DE, Vaillancourt MT, Avanzini J, Morimoto A, Demers GW, Wills KN, Shabram PW, Bolen JB, Tavtigian SV and Bookstein R (1998) Suppression of tumorigenicity of glioblastoma cells by adenovirus-mediated MMAC1/PTEN gene-transfer. Cancer Res 58: 2331-2334
7. Chumakov IM, Rigault P, Le Gall I, Bellanne-Chantelot C, Billault A, Guillou S, Soularue P, Guasconi G, Poullier E, Gros I et al (1995) A YAC contig map of the human genome. Nature 377: 175-297
8. Coy JF, Sedlacek Z, Bachner D, Delius H and Poustka A (1999) A complex pattern of evolutionary conservation and alternative polyadenylation within the long 3″-untranslated region of the methyl-CpG-binding protein 2 gene (MeCP2) suggests a regulatory role in gene expression. Hum Mol Genet 8: 1253-1262
9. Dahia PLM, FitzGerald MG, Zhang X, Marsh DJ, Zheng Z, Pietsch T, von Deimling A, Haluska FG, Haber DA and Eng C (1998) A highly conserved processed PTEN pseudogene is located on chromosome band 9p21. Oncogene 16: 2403-2406
10. Di Cristofano A, Pesce B, Cordoncardo C and Pandolfi PP (1998) PTEN is essential for embryonic-development and tumor suppression. Nat Genet 19: 348-355
11. Duerr EM, Rollbrocker B, Hayashi Y, Peters N, Meyer Puttlitz B, Louis DN, Schramm J, Wiestler OD, Parsons R, Eng C and von Deimling A (1998) PTEN mutations in gliomas and glioneuronal tumors. Oncogene 16: 2259-2264
12. Feilotter HE, Nagai MA, Boag AH, Eng C and Mulligan LM (1998) Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene 16: 1743-1748
13. Fujii GH, Morimoto AM, Berson AE and Bolen JB (1999) Transcriptional analysis of the PTEN/MMAC1 pseudogene. ψPTEN. Oncogene 18: 1765-1769
14. Giri D and Ittmann M (1999) Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma. Hum Pathol 30: 419-424
15. Gray IC, Phillips SM, Lee SJ, Neoptolemos JP, Weissenbach J and Spurr NK (1995) Loss of the chromosomal region 10q23-25 in prostate cancer. Cancer Res 55: 4800-4803
16. Gray IC, Stewart LMD, Phillips SMA, Hamilton JA, Gray NE, Watson GJ, Spurr NK and Snary D (1998) Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN. Br J Cancer 78: 1296-1300
17. Kim SK, Su LK, Oh Y, Kemp BL, Hong WK and Mao L (1998) Alterations of PTEN/MMAC1, a candidate tumor-suppressor gene, and its homolog, PTH2, in small cell lung cancer cell lines. Oncogene 16: 89-93
18. Knudson AG, Jr (1991) Overview: genes that predispose to cancer. Mutat Res 247: 185-190
19. Li DM and Sun H (1997) TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor B. Cancer Res 57: 2124-2129
20. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH and Parsons R (1997) PTEN, a putative protein-tyrosine-phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947
21. Liaw D, Marsh DJ, Li J, Dahia PLM, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M, Eng C and Parsons R (1997) Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16: 64-67
22. Maehama T and Dixon JE (1998) The tumor-suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273: 13375-13378
23. Maier D, Zhang Z, Taylor E, Hamou MF, Gratzl O, van Meir EG, Scott RJ and Merlo A (1998) Somatic deletion mapping on chromosome 10 and sequence analysis of PTEN/MMAC1 point to the 10q25-26 region as the primary target in low-grade and high-grade gliomas. Oncogene 16: 3331-3335
24. Marsh DJ, Dahia PL, Zheng Z, Liaw D, Parsons R, Gorlin RJ and Eng C (1997) Germline mutations in PTEN are present in Bannayan-Zonana syndrome [letter]. Nat Genet 16: 333-334
25. Myers MP, Stolarov JP, Eng C, Li J, Wang SI, Wigler MH, Parsons R and Tonks NK (1997) PTEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci USA 94: 9052-9057
26. Rajagopalan LE and Malter JS (1997) Regulation of eukaryotic messenger RNA turnover. Prog Nucleic Acid Res Mol Biol 56: 257-286
27. Rasheed BKA, Stenzel TT, McLendon RE, Parsons R, Friedman AH, Friedman HS, Bigner DD and Bigner SH (1997) PTEN gene mutations are seen in high grade but not in low-grade gliomas. Cancer Res 57: 4187-4190
28. Rastinejad F and Blau HM (1993) Genetic complementation reveals a novel regulatory role for 3′ untranslated regions in growth and differentiation. Cell 72: 903-917
29. Risinger JI, Hayes K, Maxwell GL, Carney ME, Dodge RK, Barrett JC and Berchuck A (1998) PTEN mutation in endometrial cancers is associated with favorable clinical and pathological characteristics. Clin Cancer Res 4: 3005-3010
30. Robertson GP, Furnari FB, Miele ME, Glendening MJ, Welch DR, Fountain JW, Lugo TG, Huang HJ and Cavence WK (1998) In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. Proc Natl Acad Sci USA 95: 9418-9423
31. Rowley G, Saad S, Giannelli F and Green PM (1995) Ultrarapid mutation detection by multiplex, solid-phase chemical cleavage. Genomics 30: 574-582
32. Steck PA, Pershouse MA, Jasser SA, Yung WKA, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DHF and Tavtigian SV (1997) Identification of a candidate tumour supressor gene, MMAC1, at chromosome 10q13.3 that is mutated in multiple advanced cancers. Nat Genet 15: 356-362
33. Tamura M, Gu J, Danen EH, Takino T, Miyamoto S and Yamada KM (1999) PTEN interactions with focal adhesion kinase and suppression of the extracellular matrix-dependent phosphatidylinositol 3-kinase/Akt cell survival pathway. J Biol Chem 274: 20693-20703
34. Tamura M, Gu J and Yamada KM (1998) Tumor suppressor PTEN inhibition of cell invasion, migration, and growth involvement of focal adhesion kinase. Mol Biol Cell 9: 1429-1429
35. Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, Li J, Parsons R and Ellenson LH (1997) Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 57: 3935-3940
36. Teng DHF, Hu R, Lin H, Davis T, Iliev D, Frye C, Swedlund B, Hansen KL, Vinson VL, Gumpper KL, Ellis L, El-Naggar A, Frazier M, Jasser S, Langford LA, Lee J, Mills GB, Pershouse MA, Pollack RE, Tornos C, Troncoso P, Yung WKA, Fujii G, Berson A, Bookstein R, Bolen JB, Tavtigian SV and Steck PA (1997) MMAC1/PTEN mutations in primary tumor specimens and tumor-cell lines. Cancer Res 57: 5221-5225
37. Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, Said JW, Isaacs WB and Sawyers CL (1998) Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA 95: 5246-5250